Can the Profitability of Medical Enterprises Be Improved After Joining China's Centralized Drug Procurement? A Difference-in-Difference Design
This paper explores the impact of joining centralized drug procurement of China on the profitability of medical enterprises by the difference-in-difference (DID) model. When centralized procurement cannot bring enough cost savings to enterprises, the price competition caused by centralized procureme...
Saved in:
Main Authors: | Yu-Fei Hua (Author), Jin Lu (Author), Bing Bai (Author), Han-Qing Zhao (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of National Centralized Drug Procurement policy on chemical pharmaceutical enterprises' R&D investment: a difference-in-differences analysis in China
by: Jiaming Li, et al.
Published: (2024) -
Impact of China's National Centralized Drug Procurement Policy on pharmaceutical enterprises' financial performance: a quasi-natural experimental study
by: Zhixuan Sun, et al.
Published: (2023) -
The impact of national centralized drug procurement on health expenditures for lung cancer inpatients: A difference-in-differences analysis in a large tertiary hospital in China
by: Yuan-jin Zhang, et al.
Published: (2022) -
The cost of total hip arthroplasty: compare the hospitalization costs of national centralized procurement and national volume-based procurement
by: Yongyong Fan, et al.
Published: (2024) -
Youth in the Netherlands Study (JOiN): study design
by: Huizink Anja C, et al.
Published: (2012)